Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride

NCT00771394 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00771394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00771394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2008
Completion date
January 31, 2010
Enrollment
638 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, benign prostatic hypertrophy, overactive bladder